Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of Directors
June 16, 2023 09:43 ET
|
Immix Biopharma, Inc.
Dr. Coleman joins the Nexcella, Inc. Board of Directors with over a decade of experience as an Independent Director of Johnson & Johnson from 2003-2016Dr. Coleman is President Emerita of the...
Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors
June 12, 2023 09:54 ET
|
Nexcella, Inc.
Dr. McKinnell joins the Nexcella, Inc. Board of Directors with 35 years of experience at Pfizer, Inc., including 6 years as Chairman and Chief Executive OfficerDr. McKinnell is a former independent...
Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors
June 12, 2023 09:49 ET
|
Immix Biopharma, Inc.
Dr. McKinnell joins the Nexcella, Inc. Board of Directors with 35 years of experience at Pfizer, Inc., including 6 years as Chairman and Chief Executive OfficerDr. McKinnell is a former...
Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site
May 26, 2023 09:58 ET
|
Nexcella, Inc.
U.S. engineering batches support planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the United States Engineering batches are the first step in transferring...
Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site
May 26, 2023 09:53 ET
|
Immix Biopharma, Inc.
U.S. engineering batches support planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the United States Engineering batches are the first step in transferring...
Nexcella Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
May 04, 2023 12:35 ET
|
Nexcella, Inc.
LOS ANGELES, May 04, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (Nasdaq: IMMX) (“Nexcella”, “Company”, “We” or “Us”) today announced that updated NXC-201 clinical data has been selected for...
Nexcella Announces Positive 58-Patient NXC- 201 Clinical Data: 100% Overall Response Rate in light chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris
April 26, 2023 17:35 ET
|
Nexcella, Inc.
Multiple Myeloma 92% was the overall response rate produced by NXC-201 in relapsed/refractory multiple myeloma patients treated at the therapeutic dose of 800 million CAR+T cells in its ongoing phase...
Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris
April 26, 2023 17:30 ET
|
Immix Biopharma, Inc.
Multiple Myeloma 92% was the overall response rate produced by NXC-201 in relapsed/refractory multiple myeloma patients treated at the therapeutic dose of 800 million CAR+T cells in its...
Nexcella Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells
March 31, 2023 08:05 ET
|
Nexcella, Inc.
LOS ANGELES, March 31, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”) today announced that an editorial written by Maria Sjöstrand and Michel Sadelain of Memorial...
Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells
March 31, 2023 08:00 ET
|
Immix Biopharma, Inc.
LOS ANGELES, March 31, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that an editorial written...